Downregulation of SIRT1 significantly attenuates the TGF-β1-induced EMT-associated migration and invasion by lung cancer cells, indicating that SIRT1 enhances cancer cell motility during EMT, and therefore represents a novel target for cancer therapies. This evidence concerns the gene SIRT1 and lung cancer.